AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

The biopharmaceutical giant AstraZeneca is considering moving their stock listing from the London Stock Exchange to the US in ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

AstraZeneca CEO discusses leaving London for US and Japan facing new, bigger tariff - Stock markets updates and business news ...

American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a ...

Citing multiple sources, the Times said AstraZeneca CEO Pascal Soriot has spoken privately of his preference to move the FTSE 100 company's listing on a number of occasions and has even discussed ...

--Pascal Soriot expressed his preference for a change in listing location on several occasions, and also discussed changing the company's domicile, The Times says, citing one source. --Such a decision ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...